Pfizer lays out MRSA vaccine battle plan

Reuters has looked inside the Pfizer ($PFE) lab tasked with developing a vaccine for the drug-resistant superbug MRSA. Merck ($MRK) flunked late phase trials in 2011, but a host of drugmakers are still in the race. Pfizer thinks its multipronged approach can stop the bacterium. Feature

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.